Literature DB >> 7685194

Long-term correction of neutropenia in Felty's syndrome with granulocyte colony-stimulating factor.

H Wandt1, M Seifert, C Falge, W M Gallmeier.   

Abstract

Neutropenia in Felty's Syndrome predisposes patients to recurrent bacterial infections. We have treated a patient for more than one year with G-CSF and ascertained that this growth factor can safely correct neutropenia over a long period of time. G-CSF may constitute a new agent for the treatment and prophylaxis of infection in Felty's syndrome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685194     DOI: 10.1007/bf01738478

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

1.  GM-CSF versus G-CSF in the treatment of infectious complication in Felty's syndrome--a case report.

Authors:  U Kaiser; M Klausmann; G Richter; K H Pflüger
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

2.  Granulocyte-macrophage colony-stimulating factor treatment of neutropenia associated with Felty's syndrome.

Authors:  H M Markusse; F C Breedveld; W E Fibbe
Journal:  Arthritis Rheum       Date:  1990-12

3.  Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis.

Authors:  B P Hazenberg; M A Van Leeuwen; M H Van Rijswijk; A C Stern; E Vellenga
Journal:  Blood       Date:  1989-12       Impact factor: 22.113

4.  GM-CSF in the treatment of Felty syndrome.

Authors:  G Joseph; D H Neustadt; J Hamm; M Kellihan; T Hadley
Journal:  Am J Hematol       Date:  1991-05       Impact factor: 10.047

5.  Heterogeneity of bone marrow-directed immune mechanisms in the pathogenesis of neutropenia of Felty's syndrome.

Authors:  N I Abdou
Journal:  Arthritis Rheum       Date:  1983-08
  5 in total
  1 in total

1.  Erysipelas in neutropenia of unknown origin, successfully treated with r-metHuG-CSF (filgrastim)

Authors:  M Müller-Lühr; N Breyer; A Martin; H Haacke
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.